@article{ed19114be3bd46b49870ceacccea7ba0,
title = "Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae – Authors' reply",
author = "Bel{\'e}n Guti{\'e}rrez-Guti{\'e}rrez and Bonomo, {Robert A.} and Yehuda Carmeli and Paterson, {David L.} and Alvaro Pascual and Jes{\'u}s Rodr{\'i}guez-Ba{\~n}o",
note = "Funding Information: JRB has been a scientific advisor for AstraZeneca, Merck, and InfectoPharm in research projects, and has been speaker at accredited educational courses funded by unrestricted grants from Merck. RAB received grants for research from NIH, Veteran Affairs, Allergan, Merck, Roche, Wockhardt, and Entasis. YC received grants, honoraria, travel support, consulting fees, and other forms of financial support from Achaogen, Allecra Therapeutics, AstraZeneca, Basilea Pharmaceutica, Biomerieux, Cepheid, DaVolterra, Durata Therapeutics, Intercell AG, Merck, PPD is not an acroninum, is the name of a company, as stated. So no definition possible., Proteologics, Rempex Pharmaceuticals, Rib-X Pharmaceuticals, Syntezza Bioscience, and Takeda Pharmaceutical. DLP has received honoraria for advisory board participation from Merck, AstraZeneca, Cubist, Pfizer, and Novartis. AP has been a speaker for Merck and B Braun; he has been scientific advisor for Merck and has received unrestricted research grants from B Braun and AstraZeneca . DLP has been on advisory boards for Merck, Shionogi, GSK, Meiji, Achaogen, and Pfizer, and has grant support from Merck. BGG declares no competing interests.",
year = "2017",
month = oct,
doi = "10.1016/S1473-3099(17)30522-4",
language = "אנגלית",
volume = "17",
pages = "1020--1021",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "10",
}
